[{"address1": "175 Innovation Boulevard", "city": "Wilmington", "state": "DE", "zip": "19805", "country": "United States", "phone": "302 467 1280", "website": "https://preludetx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.", "fullTimeEmployees": 128, "companyOfficers": [{"maxAge": 1, "name": "Dr. Krishna  Vaddi D.V.M., Ph.D.", "age": 58, "title": "Founder, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 905916, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Edna  Huang M.D.", "age": 51, "title": "President & Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 865629, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Aimee  Crombie Ph.D.", "title": "Senior VP and Head of Strategic Planning & Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Madhu  Pudipeddi Ph.D.", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peggy A. Scherle Ph.D.", "age": 62, "title": "Chief Scientific Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 868617, "exercisedValue": 0, "unexercisedValue": 436567}, {"maxAge": 1, "name": "Ms. Michele  Porreca M.B.A.", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew P. Combs Ph.D.", "age": 58, "title": "Executive VP & Chief Chemistry Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 562461, "exercisedValue": 0, "unexercisedValue": 399432}, {"maxAge": 1, "name": "Mr. Naveen  Babbar Ph.D.", "title": "Senior Vice President of Translation Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William B. Novotny M.D.", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Wan-Jen  Hong M.D.", "age": 45, "title": "Senior Vice President of Clinical Development", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.95, "open": 0.9409, "dayLow": 0.9409, "dayHigh": 1.01, "regularMarketPreviousClose": 0.95, "regularMarketOpen": 0.9409, "regularMarketDayLow": 0.9409, "regularMarketDayHigh": 1.01, "beta": 1.363, "forwardPE": -0.6481791, "volume": 169677, "regularMarketVolume": 169677, "averageVolume": 443318, "averageVolume10days": 232980, "averageDailyVolume10Day": 232980, "bid": 0.9556, "ask": 0.9989, "bidSize": 100, "askSize": 100, "marketCap": 53384144, "fiftyTwoWeekLow": 0.797, "fiftyTwoWeekHigh": 6.8, "priceToSalesTrailing12Months": 17.794714, "fiftyDayAverage": 1.0877, "twoHundredDayAverage": 2.89762, "currency": "USD", "enterpriseValue": -82105888, "floatShares": 13890327, "sharesOutstanding": 42184900, "sharesShort": 3149039, "sharesShortPriorMonth": 3381616, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0572, "heldPercentInsiders": 0.09359, "heldPercentInstitutions": 0.85087997, "shortRatio": 11.06, "shortPercentOfFloat": 0.1816, "impliedSharesOutstanding": 55035200, "bookValue": 2.843, "priceToBook": 0.3411889, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -131517000, "trailingEps": -1.77, "forwardEps": -1.51, "enterpriseToRevenue": -27.369, "enterpriseToEbitda": 0.58, "52WeekChange": -0.7716346, "SandP52WeekChange": 0.22903383, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "PRLD", "underlyingSymbol": "PRLD", "shortName": "Prelude Therapeutics Incorporat", "longName": "Prelude Therapeutics Incorporated", "firstTradeDateEpochUtc": 1601040600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "b4d5f445-4c0f-32e5-9fdb-a86b330519d9", "messageBoardId": "finmb_373775974", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.97, "targetHighPrice": 10.0, "targetLowPrice": 1.0, "targetMeanPrice": 5.0, "targetMedianPrice": 4.5, "recommendationKey": "none", "numberOfAnalystOpinions": 4, "totalCash": 153626000, "totalCashPerShare": 2.791, "ebitda": -141648000, "totalDebt": 18136000, "quickRatio": 6.913, "currentRatio": 7.037, "totalRevenue": 3000000, "debtToEquity": 11.594, "revenuePerShare": 0.04, "returnOnAssets": -0.39294997, "returnOnEquity": -0.66643995, "grossProfits": 3000000, "freeCashflow": -61550752, "operatingCashflow": -105722000, "grossMargins": 1.0, "operatingMargins": -11.45867, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]